HDAC3 and atherosclerosis: HDAC3 and HDAC9 are promising targets, and apabetalone, a bromodomain and extraterminal (BET) protein inhibitor, attenuates inflammation, but its efficacy to attenuate atherosclerosis and cardiovascular diseases has not been established yet [111].